Hostname: page-component-586b7cd67f-tf8b9 Total loading time: 0 Render date: 2024-11-25T19:57:37.507Z Has data issue: false hasContentIssue false
  • English
  • Français

Effects of a Tyramine-Enriched Meal on Blood Pressure Response in Healthy Male Volunteers Treated with Selegiline Transdermal System 6 mg/24 Hour

Published online by Cambridge University Press:  07 November 2014

Lawrence F. Blob ,
Melvin Sharoky ,
Bryan J. Campbell ,
Eva M. Kemper ,
Michelle Gilmor ,
Chad M. VanDenBerg  and
Albert J. Azzaro
Get access Rights & Permissions [Opens in a new window]

Abstract

Background:

Monoamine oxidase inhibitors are well recognized as effective antidepressant agents but are rarely used due, in part, to the risk of hypertensive crisis following the ingestion of foods high in tyramine (“cheese reaction”). A selegiline transdermal system (STS) was developed to provide antidepressant concentrations of selegiline in the brain, while preserving the gastrointestinal monoamine oxidase A (MAO-A) barrier. The present study was conducted to determine the effect of the STS 6 mg/24 hour on cardiovascular safety following the ingestion of ∼400 mg of tyramine consumed as a component of aged cheeses.

Methods:

In this open-label, single-center phase I study, cardiovascular vital signs were recorded following tyramine challenges during placebo and STS 6 mg/24 hr treatment. Subjects were observed for clinical signs and symptoms of a pressor response and/or potential hypertensive crisis during and following the challenges.

Results:

Ingestion of tyramine-enriched meals following 13 consecutive days of treatment with the STS 6 mg/24 hr (pharmacokinetic steady-state) produced no clinically significant changes in cardiovascular vital signs in 12 healthy adult male subjects. No evidence of a tyramine pressor effect on systolic blood pressure or evidence of hypertensive crisis occurred during the STS treatment.

Conclusion:

These results suggest that STS 6 mg/24 hr may be administered without concern for dietary tyramine consumption.

Type
Original Research
Information
CNS Spectrums , Volume 12 , Issue 1 , January 2007 , pp. 25 - 34
Copyright
Copyright © Cambridge University Press 2007

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.VanDenBerg, CM, Blob, LF, Kemper, EM, Azzaro, AJ. Tyramine pharmacokinetics and reduced bioavailability with food. J Clin Pharmacol. 2003;43:604–609.CrossRefGoogle Scholar
2.Sen, NP. Analysis and Significance of Tyramine in Foods. J Food Sci. 1969;34:22–26.CrossRefGoogle Scholar
3.McCabe, BJ. Dietary tyramine and other pressor amines in MAOI regimens: a review. J Am Diet Assoc. 1986;86:1059–1064.CrossRefGoogle ScholarPubMed
4.Gardner, DM, Shulman, KI, Walker, SE, Tailor, SA. The making of a user friendly MAOI diet. J Clin Psychiatry. 1996;57:99–104.Google ScholarPubMed
5.Da Prada, M, Zurcher, G, Wuthrich, I, Haefely, WE. On tyramine, food, beverages and the reversible MAO inhibitor moclobemide. J Neural Transm Suppl. 1988;26:31–56.Google ScholarPubMed
6.Horwitz, D, Lovenberg, W, Engelman, K, Sjoerdsma, A. Monoamine oxidase inhibitors, tyramine, and cheese. JAMA. 1964;188:1108–1110.CrossRefGoogle Scholar
7.Blackwell, B, Marley, E, Price, J, Taylor, D. Hypertensive interactions between monoamine oxidase inhibitors and foodstuffs. Br J Psychiatry. 1967;113:349–365.CrossRefGoogle ScholarPubMed
8.Folks, DG. Monoamine oxidase inhibitors: reappraisal of dietary considerations. J Clin Psychopharmacol. 1983;3:249–252.CrossRefGoogle ScholarPubMed
9.Brown, C, Taniguchi, G, Yip, K. The monoamine oxidase inhibitor-tyramine interaction. J Clin Pharmacol. 1989;29:529–532.CrossRefGoogle ScholarPubMed
10.Asatoor, AM, Levi, AJ, Milne, MD. Tranylcypromine and cheese. Lancet. 1963;54:733–734.CrossRefGoogle Scholar
11.Sandler, M, Glover, V, Ashford, A, Esmail, A. The inhibition of tyramine oxidation and the tyramine hypertensive response (“cheese effect”) may be independent phenomena. J Neural Transm. 1980;48:241–247.CrossRefGoogle Scholar
12.Ghose, K. Tyramine pressor test: implications and limitations. Methods Find Exp Clin Pharmacol. 1984;6:455–464.Google ScholarPubMed
13.Chobanian, AV, Bakris, GL, Black, HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206–1252.CrossRefGoogle ScholarPubMed
14.Bieck, PR, Antonin, KH. Oral tyramine pressor test and the safety of monoamine oxidase inhibitor drugs: comparison of brofaromine and tranylcypromine in healthy subjects. J Clin Psychopharmacol. 1988;8:237–245.CrossRefGoogle ScholarPubMed
15.Berlin, I, Zimmer, R, Cournot, A, Payan, C, Pedarriosse, AM, Puech, AJ. Determination and comparison of the pressor effect of tyramine during long-term moclobemide and tranylcypromine treatment in healthy volunteers. Clin Pharmacol Ther. 1989;46:344–351.CrossRefGoogle ScholarPubMed
16.Shulman, KI, Walker, SE, MacKenzie, S, Knowles, S. Dietary restriction, tyramine, and the use of monoamine oxidase inhibitors. J Clin Psychopharmacol. 1989;9:397–402.CrossRefGoogle ScholarPubMed
17.Shulman, KI, Walker, SE. Refining the MAOI diet: tyramine content of pizzas and soy products. J Clin Psychiatry. 1999;60:191–193.CrossRefGoogle ScholarPubMed
18.Youdim, MB, Weinstock, M. Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation. Neurotoxicology. 2004;25:243–250.CrossRefGoogle Scholar
19.Heinonen, EH, Myllyla, V. Safety of selegiline (deprenyl) in the treatment of Parkinson's disease. Drug Saf. 1998;19(1):11–22.CrossRefGoogle ScholarPubMed
20.Chrisp, P, Mammen, GJ, Sorkin, EM. Selegiline. A review of its pharmacology, symptomatic benefits and protective potential in Parkinson's disease. Drugs Aging. 1991;1:228–248.CrossRefGoogle ScholarPubMed
21.Knoll, J. Deprenyl (selegiline): the history of its development and pharmacological action. Acta Neurol Scand Suppl. 1983;95:57–80.CrossRefGoogle ScholarPubMed
22.Elsworth, JD, Glover, V, Reynolds, GP, et al. Deprenyl administration in man: a selective monoamine oxidase B inhibitor without the ‘cheese effect.’ Psychopharmacol (Berl). 1978;57:33–38.CrossRefGoogle Scholar
23.McGrath, PJ, Stewart, JW, Harrison, W, Wager, S, Nunes, EN, Quitkin, FM. A placebo-controlled trial of L-deprenyl in atypical depression. Psychopharmacol Bull. 1989;25:63–67.Google ScholarPubMed
24.Mendlewicz, J, Youdim, MB. L-Deprenil, a selective monoamine oxidase type B inhibitor, in the treatment of depression: a double blind evaluation. Br J Psychiatry. 1983;142:508–511.CrossRefGoogle ScholarPubMed
25.Mann, JJ, Aarons, SF, Wilner, PJ, et al. A controlled study of the antidepressant efficacy and side effects of (–)-deprenyl: a selective monoamine oxidase inhibitor. Arch Gen Psychiatry. 1989;46:45–50.CrossRefGoogle ScholarPubMed
26.Sunderland, T, Cohen, RM, Molchan, S, et al. High-dose selegiline in treatment-resistant older depressive patients. Arch Gen Psychiatry. 1994;51:607–615.CrossRefGoogle ScholarPubMed
27.Schulz, R, Antonin, KH, Hoffmann, E, et al. Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline. Clin Pharmacol Ther. 1989;46:528–536.CrossRefGoogle ScholarPubMed
28.Lipper, S, Murphy, DL, Slater, S, Buchsbaum, MS. Comparative behavioral effects of clorgyline and pargyline in man: a preliminary evaluation. Psychopharmacology (Berl). 1979;62:123–128.CrossRefGoogle ScholarPubMed
29.Sunderland, T, Mueller, EA, Cohen, RM, Jimerson, DC, Pickar, D, Murphy, DL. Tyramine pressor sensitivity changes during deprenyl treatment. Psychopharmacology (Berl). 1985;86:432–437.CrossRefGoogle ScholarPubMed
30.Bodkin, JA, Amsterdam, JD. Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients. Am J Psychiatry. 2002;159:1869–1875.CrossRefGoogle ScholarPubMed
31.Amsterdam, JD. A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. J Clin Psychiatry. 2003;64:208–214.CrossRefGoogle ScholarPubMed
32.Barrett, JS, Hochadel, TJ, Morales, RJ, et al. Pharmacokinetics and Safety of a Selegiline Transdermal System Relative to Single-Dose Oral Administration in the Elderly. Am J Ther. 1996;3:688–698.CrossRefGoogle ScholarPubMed
33.Rohatagi, S, Barrett, JS, DeWitt, KE, Morales, RJ. Integrated pharmacokinetic and metabolic modeling of selegiline and metabolites after transdermal administration. Biopharm Drug Dispos. 1997;18:567–584.3.0.CO;2-7>CrossRefGoogle ScholarPubMed
34.Wecker, L, James, S, Copeland, N, Pacheco, MA. Transdermal selegiline: targeted effects on monoamine oxidases in the brain. Biol Psychiatry. 2003;54:1099–1104.CrossRefGoogle ScholarPubMed
35.Mawhinney, M, Cole, D, Azzaro, AJ. Daily transdermal administration of selegiline to guinea-pigs preferentially inhibits monoamine oxidase activity in brain when compared with intestinal and hepatic tissues. J Pharm Pharmacol. 2003;55:27–34.CrossRefGoogle ScholarPubMed
36.Azzaro, AJ, VanDenBerg, CM, Blob, LF, et al. Tyramine pressor sensitivity during treatment with the selegiline transdermal system 6 mg/24 h in healthy subjects. J Clin Pharmacol. 2006;46:933–944.CrossRefGoogle Scholar
37.Handbook of Clinical Dietetics. 2nd ed. New Haven, CT: Yale University Press; 1992.Google Scholar
38.Lader, MH, Sakalis, G, Tansella, M. Interactions between sympathomimetic amines and a new monoamine oxidase inhibitor. Psychopharmacologia. 1970;18:118–123.CrossRefGoogle Scholar
39.Pickering, TG, Harshfield, GA, Kleinert, HD, Blank, S, Laragh, JH. Blood pressure during normal daily activities, sleep, and exercise. Comparison of values in normal and hypertensive subjects. JAMA. 1982;247:992–996.CrossRefGoogle ScholarPubMed
40.Walker, SE, Shulman, Kl, Tailor, SA, Gardner, D. Tyramine content of previously restricted foods in monoamine oxidase inhibitor diets. J Clin Psychopharmacol. 1996;16:383–388.CrossRefGoogle ScholarPubMed
41.Reimann, IW, Firkusny, L, Antonin, KH, Bieck, PR. Intravenous amine pressor tests in healthy volunteers. Within- and between subject variances and sex differences. Eur J Clin Pharmacol. 1992;42:137–141.CrossRefGoogle ScholarPubMed
42.Cantarini, MV, Painter, CJ, Gilmore, EM, Bolger, C, Watkins, CL, Hughes, AM. Effect of oral iinezolid on the pressor response to intravenous tyramine. Br J Clin Pharmacol. 2004;58:470–475.CrossRefGoogle Scholar
43.Blackwell, B, Mabbitt, LA. Tyramine in cheese related to hypertensive crises after monoamine-oxidase inhibition. Lancet. 1965;62:938–940.CrossRefGoogle Scholar